Selected transactions

Exclusive Financial Advisor to Mesotherapy leader Suisselle in the structuring of the strategic partnership for the licensing of their novel skinbooster “Cellbooster” to Chinese partner Sihuan Pharmaceuticals.

Advisor to Bridgepoint in the acquisition of a majority stake in Laboratoire Vivacy SA.

Financial Advisor to Bridgepoint in divesting a majority in HTL Biotech, a pharmaceutical-grade Hyaluronic Acid (Hyaluronan) and other Glycosaminoglycans (GAGs) and other functional Biopolymers such as PDRN or Polynucleotides (PN) to Montagu.

Advisor in the completion of a € 10m share capital increase and realization of a Fairness Opinion for Market Valuation.

Exclusive Financial Advisor to Nicox for the sale of the remaining stake in VISUfarma to GHO Capital.

Exclusive Financial Advisor to BMG Pharma to enter a Distribution, Supply and Licensing Agreement covering a range of Oral-Care brands with Pierre Fabre Médicament.

Share Capital Increase via preferred Convertible Offering to a consortium of new investors to support international deployment.

Exclusive Financial Advisor to the Largest Polish Medical Aesthetic Group for the Divestiture of a 51% stake to Abris Capital, a Polish Growth Capital PE Fund and concurrent Entry into a Shareholders’ Agreement.

Exclusive Financial Advisor in the Divestiture to the of Sothys SA’s 66.67% stake in Simone Mahler, the French dermo-cosmetic player operating a network of Natural Health Beauty Spas (« Instituts Mahler »), to Simone Mahler’s Management.

Exclusive Financial Advisor to Universkin for the completion of a strategic distribution agreement with Croma-Pharma GmbH and divestiture of a 5% stake to Croma.

Exclusive Financial Advisor to Nicox for the Transfer of its European commercial operations to a newly-founded company focused on ophthalmic products in Europe.

Exclusive Financial Advisor to Delife Srl and Relivia Srl on their sale to A. Menarini Industrie Farmaceutiche Riunite Srl.